Adial Pharmaceuticals Files Prospectus Related To The Proposed Resale Of Up To 25,148,970 Shares Of Common Stock By Selling Stockholders
-SEC Filing
Stocks · News reference
LUCID CAPITAL MARKETS Initiates Coverage On Adial Pharmaceuticals with Buy Rating, Announces Price Target of $6
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — ADIAL PHARMACEUTICALS, INC. (ADIL)
Filed: 2026-08-25 AccNo: 0001213900-26-093544 Size: 188 KB Item 3.02: Unregistered Sales of Equity Securities
Adial Pharmaceuticals shares are trading lower after the company reported a wider net loss for the second quarter.
Adial Pharmaceuticals Q2 EPS $(11.25)